Perspective - Research and Reports on Genetics (2022) Volume 4, Issue 5
Effect of RNA polymerase homologous in DNA recombination
Naser Ahmadbeigi *
Department of Otorhinolaryngology-Head and Neck Surgery, Zhongnan Hospital of Wuhan University, China
- *Corresponding Author:
- Naser Ahmadbeigi
Department of Otorhinolaryngology-Head and Neck Surgery
Zhongnan Hospital of Wuhan University
Received: 29-Aug-2022, Manuscript No. AARRGS-22-77617; Editor assigned: 02-Aug-2022, PreQC No. AARRGS-22-77617(PQ); Reviewed: 16-Sep-2022, QC No. AARRGS-22-77617; Revised: 19-Sep-2022, Manuscript No. AARRGS-22-77617 (R); Published: 26-Sep-2022, DOI:10.35841/aarrgs-4.5.123
Citation: Ahmadbeigi N. An overview of Gene Therapy for Cancer. J Res Rep Genet. 2022;4(5):123
Clinical trials, Gene therapy, Genetic diseases.
Since the cloning of the human genome in the application of gene therapy to cancer has only recently been realized. This has evolved from advances in our understanding of genetic mutations in patient cancer cells and faster diagnostic testing capabilities that enable the detection of the genetic status of individual tumours. Additionally, advances in cancer immunology have spawned several new drugs, including checkpoint inhibitors, vaccines, oncolytic viruses and CAR-T cells
Recent advances in cell and gene therapy have enabled the treatment of a wide range of diseases, from congenital diseases to solid tumours. Many efforts have been made since the first gene therapy in and several gene therapy products have been approved in recent years, ushering in a new era of gene therapy. Several milestones in the gene therapy research trajectory have paved the way for translating science into products from bench to bedside provide valuable information for improved study design, and realistic policy design for gene therapy research centers .
The purpose of this review was to provide an overview of gene therapy clinical trials and analyze current trends with a focus on gene therapy strategies. This study reviewed clinical trial information from Clinical trials. A flow chart for the inclusion of clinical studies that extracted data from the remaining studies that screened duplicate search results by title is shown in figure. Data extracted for final analysis should include publication information type of vector used, type of cell or target tissue manipulated, type of cell or target tissue introduced, genes, ex vivo or in vivo gene therapy modalities, clinical trial stages, disease groups followed by subcategories, and specific diseases for which gene therapy is used. It should be noted that if any of the evaluated variables were indeterminate or unattainable, they were excluded from the analysis. After extracting study status, clinical studies that were discontinued, interrupted, or were excluded .
Surgeons are increasingly being asked to obtain tissue for diagnostic, therapeutic, and biomarker purposes in patients undergoing gene therapy. Early preoperative consultation with a pathologist and medical oncologist is important to ensure proper tumours specimen selection, surgical procedures, tissue handling, and specimen processing. Surgeons may also be asked to provide access to tissue to perform gene therapy using open, laparoscopic, and endoscopic approaches. The cistron medical care journey began once Wilhelm Johansen coined the term "gene". Crick and James Watson discovered the helix structure of deoxyribonucleic acid regarding a century later. The term "genetic engineering" was 1st employed in the Nineteen Thirties. the fundamental principle of cistron transfer in microorganism was discovered in his Nineteen Sixties and afterward tailored for the event of eukaryotic transfection techniques represented within the Seventies, restriction and ligature enzymes kind the premise of biotechnology recombinant deoxyribonucleic acid technology has enabled researchers to introduce therapeutic genes of selection into built vectors. With the invention of the power of viruses to transfer genetic material, infectious agent vectors have emerged as promising and effective tools for cistron transfer. These technological advances have allowed scientists to form cistron medical care vectors which will deliver specific genetic material to targeted class cells .
Typically, therapeutic factor medical care transfers geneticmaterial into cells to reverse abnormal conditions or inducenew traits. completely different ways like addition, pieceof writing and deletion knockout is used, betting on theunderlying genetic drawback factor medical care is typicallyaccustomed add traditional, useful copies of alleles to extendorganic phenomenon. Add a standard human plasma proteinIX gene to supply sufficient Christmasfactor in blood disordertype B. Factor medical care is typically accustomed introducealtered alleles into cells to administer them new traits,automotive structure in CAR-T cells or suicide genes such asdeoxythymidine kinase in cancer cells. Some factor therapiesar used for vaccination, chiefly by introducing specific antigensto stimulate the system. This strategy has gained explicitattention within the development of COVID-19 vaccines.Factor medical care could also be accustomed repair or editmutated defective allele. Correction of Survival Nerve celltwo (SMN2) factor transcription by antisense oligonucleotidesin spinal muscular atrophy could be a valuable tool duringthis mechanism. Inactivating abnormal or defective genes,like victimization siRNA (antisense oligonucleotides) orCRISPR to degrade TTR template RNA and scale back TTRmacromolecule production in the treatment .
Gene therapy is making inroads into various fields. Starting with genetic diseases, gene therapy now plays a pioneeringrole in many other fields. After reviewing gene therapy clinicaltrials from to it was concluded that they could be grouped intothree main areas: cancer, monogenic and polygenic diseasesgenetic sexually transmitted diseases, infectious diseases andother research.
- Miller AR, Economou JS.Cytokine-mediated gene therapy for cancer. Ann Surg Oncol. 1994;1(5):436-50.
- El-Aneed A.An overview of current delivery systems in cancer gene therapy. JCR 2004;94(1):1-4.
- Seth P.Vector-mediated cancer gene therapy: an overview. Cancer BiolTher. 2005 ;4(5):512-7.
- Pahle J, Walther W Vectors and strategies for nonviral cancer gene therapy. Expert Opin Biol Ther. 2016;16(4):443-61.
- Kogoma T . Stable DNA replication: interplay between DNA replication, homologous recombination, and transcription. Mol Biol Rev. 1997;61(2):212-38.